High dose arachidonic and docosahexaenoic acid in very preterm infants and neurodevelopment at 2 years - A double-blind randomized controlled trial
Clinical Nutrition · 2025
DOI: 10.1016/j.clnu.2025.05.019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nutrition, 2025. Verfasst von Gunnthorunn Gunnarsdottir und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway. Electronic address: …. Hauptthemen laut MEDLINE: Docosahexaenoic Acids, Arachidonic Acid, Dietary Supplements, Child Development. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway, South-Eastern Norway Regional Health Authority.
Themen: Neonatologie
Abstract (Originalsprache)
BACKGROUND AND AIMS: The fatty acids arachidonic acid (ARA) and docosahexaenoic acid (DHA) accumulate in neural tissue in the last trimester, thus preterm infants have lower levels compared to their term-born peers. Our aim was to evaluate the impact of ARA and DHA supplementation in very preterm infants on neurodevelopmental outcomes at two years corrected age (CA). We also wanted to study the effect of in-hospital growth, socioeconomic factors and other possible covariates on neurodevelopmental outcomes for the entire study population. METHODS: This is a follow-up study of the ImNuT-trial (NCT03555019); a randomized controlled trial (RCT), where 120 infants born before 29 weeks of gestational age (GA) were randomized to receive an enteral supplement of both ARA and DHA (ARA:DHA group) or medium chain triglycerides (control group). The infants received supplementation from the second day of life until 36 weeks postmenstrual age (PMA). At two years CA, the children underwent neurodevelopmental assessment using Bayley Scales of Infant and Toddler Development, third edition (BSID-III) and Peabody Developmental Motor Scales second edition (PDMS-2). RESULTS: Mean (SD) GA at birth was 26.4 (1.7) weeks. The mean (SD) corrected age at follow-up was 24 months + 7 days (17 days). There were no significant differences in neurodevelopmental outcomes between the treatment groups. The multivariable regression model showed a positive association between female sex and motor scores as well as maternal education level and language scores. Faster linear growth from day 28-36 weeks PMA was associated with higher cognitive scores. Non-Scandinavian family language was negatively associated with all three BSID-scores. CONCLUSION: Supplementation with ARA and DHA in very preterm children did not result in significant differences in neurodevelopmental outcomes assessed with BSID-III and PDMS-2 at 2 years corrected age. Higher maternal education level, female sex, faster linear growth during hospitalization and Scandinavian family language were predictive of neurodevelopmental outcome. TRIAL REGISTRATION: Clinicaltrials.gov ID NCT03555019.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Neurology, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway. Electronic address: gunngu@ous-hf.no.
- Department of Pediatrics and Adolescence Medicine, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway.
- Department of Neonatal Intensive Care, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway.
- Department of Pediatric Neurology, Oslo University Hospital, Norway.
- Department of Pediatrics and Adolescence Medicine, Oslo University Hospital, Norway.
- Department of Pediatric Neurology, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway.
Förderung
- Research Council of Norway
- South-Eastern Norway Regional Health Authority
Zitieren
APA
Gunnarsdottir, G., Rossholt, M. E., Nordvik, T., Wendel, K., Aas, M. F., Skarbø, A. B., Aulie, V. S., Stiris, T., Ramm-Pettersen, A., Pfeiffer, H. C., & Moltu, S. J. (2025). High dose arachidonic and docosahexaenoic acid in very preterm infants and neurodevelopment at 2 years - A double-blind randomized controlled trial. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.05.019
Vancouver
Gunnarsdottir G, Rossholt ME, Nordvik T, Wendel K, Aas MF, Skarbø AB, et al. High dose arachidonic and docosahexaenoic acid in very preterm infants and neurodevelopment at 2 years - A double-blind randomized controlled trial. Clinical Nutrition. 2025. doi:10.1016/j.clnu.2025.05.019
BibTeX
@article{Gunnarsdottir2025,
author = {Gunnarsdottir, Gunnthorunn and Rossholt, Madelaine Eloranta and Nordvik, Tone and Wendel, Kristina and Aas, Marlen Fossan and Skarbø, Anne-Britt and Aulie, Vibeke Smih and Stiris, Tom and Ramm-Pettersen, Anette and Pfeiffer, Helle C and Moltu, Sissel J},
title = {High dose arachidonic and docosahexaenoic acid in very preterm infants and neurodevelopment at 2 years - A double-blind randomized controlled trial},
journal = {Clinical Nutrition},
year = {2025},
doi = {10.1016/j.clnu.2025.05.019}
}
EUVIMED